ObsEva SA (OBSV) Set to Announce Earnings on Tuesday
ObsEva SA (NASDAQ:OBSV) is scheduled to post its quarterly earnings results after the market closes on Tuesday, August 15th. Analysts expect ObsEva SA to post earnings of ($0.48) per share for the quarter.
ObsEva SA (NASDAQ:OBSV) last issued its earnings results on Thursday, May 18th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.17. On average, analysts expect ObsEva SA to post $-2.09 EPS for the current fiscal year and $-2.09 EPS for the next fiscal year.
Shares of ObsEva SA (NASDAQ:OBSV) traded up 2.02% during midday trading on Tuesday, hitting $8.08. 17,214 shares of the company’s stock were exchanged. The company has a 50-day moving average of $7.40 and a 200-day moving average of $9.26. ObsEva SA has a 52 week low of $5.00 and a 52 week high of $14.69. The firm’s market cap is $215.11 million.
WARNING: “ObsEva SA (OBSV) Set to Announce Earnings on Tuesday” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/08/08/obseva-sa-obsv-set-to-announce-earnings-on-tuesday.html.
Several research firms have recently weighed in on OBSV. HC Wainwright began coverage on shares of ObsEva SA in a report on Thursday, June 29th. They issued a “buy” rating and a $27.00 price target for the company. Zacks Investment Research upgraded shares of ObsEva SA from a “sell” rating to a “hold” rating in a report on Wednesday, July 19th. Finally, Credit Suisse Group reiterated an “outperform” rating and issued a $27.00 price target on shares of ObsEva SA in a report on Tuesday, April 18th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $24.00.
ObsEva SA Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.